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Rat Steroid 5a-Reductase Kinetic 
Characteristics: Extreme pH -dependency of
the Type II Isozyme in Prostate and
Epididymis Homogenates
P. N. Span,1* A. G. H. Smals, 1 C. G. J. Sweep2 and Th. J. Benraad2
1 • » * * *  * 2 * * % Department o f Medicine, Division o f Endocrinology and Department o f Experimental and Chemical Endocrinology,
University Hospital, Nijmegen, The Netherlands
Reevaluating the assay for rat steroid 5a-reductase isozymes in prostate and epididymis homogenates 
we encountered an extreme pH-dependency of the type II isozyme. The tim e-course o f the metabo­
lism of testosterone (T) to 17/J-hydroxy-5a-androstan-3-one (DHT) at acidic pH shows an initial 
burst when the homogenate is not brought to pH before the start of the incubation. Therefore, the 
rat type II 5a-reductase isozyme does not follow Michaelian law under these conditions making a sin­
gle time point measurement invalid. Assessing the pH-optimum of 5a-reduction in both rat prostate 
and epididymis homogenates we found a strong substrate dependency: at high substrate concentra­
tions a pH-optimum for the type II isozyme of pH 5.0 was found, whereas at lower concentrations 
pH 5.5 is optimal. Establishing Fmax (maximum velocities) and Km (affinity constants) for the 5a- 
reduction of T at pH 4.5-8.0, the efficiency optimum FmaJKj^ appeared to be pH 5.5 in both prostate 
and epididymis homogenates. Specifically at acidic pH these kinetic characteristics of the type II iso­
zyme vary many-fold. Discrepancies in literature concerning 5a-reductase characteristics can, at 
least in part, be attributed to the choice of optimal pH, or to pH shifts during the assay.
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INTRODUCTION
Steroid 5a-reductase (5oc-reductase E.C. 1.3.99.5) is a 
NADPH-dependent enzyme capable of 5a-re during a 
number of steroids with a 4,5 double bond and a 3- 
oxo group., including glucocorticoids, progestogens, 
miner alocortico ids, androgens [1] and non-androgens 
such as the pheromone precursor 4,16-androstadien- 
3-one [2, 3].
5a~Reductase can serve an anabolic purpose* cata­
lyzing the conversion of testosterone (T) into the 
more potent androgen dihydrotestosterone (DHT)
[4]. DHT binds with higher affinity to the androgen 
receptor than does T  [5, 6]. DH T has been impli­
cated in the pathogenesis of benign prostatic hyperpla­
sia (BPH), prostate cancer, acne vulgaris, androgenic 
alopecia and hirsutism [7-11]. 5a-Reductase can also 
play a catabolic role, as 5a-reduced metabolites are 
susceptible to 3a/3jS-reduction. These 3-hydroxylated
* Correspondence to P. N. Span.
Received 25 Nov. 1994; accepted 17 Mar. 1995.
metabolites can be excreted after subsequent hydroxy- 
lation or conjugation.
In 1970, Voigt et a l  described a 5a-reductase with 
a pH-optimum of 5.5 in homogenates o f human fore­
skin [12]. It was not until 1976 that Moore and 
Wilson postulated the existence of two 5a-reductase 
subtypes with distinct pH-optima [13], later desig­
nated type I and II according to the chronological 
order in which their cD N A ’s were isolated [14-17]. 
Research on patients with a type II 5a-reductase defi­
ciency (pseudohermaphroditism) has underlined the 
importance of the type II isozyme in the development 
of several androgen-dependent organs [18-20]. This 
signifies an anabolic role of this type II isozyme. The 
role of the type I 5a-reductase isozyme is not known 
as patients with a deficiency have not yet been 
described, but is assumed to be catabolic [14].
The 5a-reductase isozymes are highly conserved as 
rat and human tissues both exhibit two subtypes [14- 
17, 21, 22]. Amino acid sequence homology between 
rat and human subtypes is higher than between type I 
and type II of either species [1]. Both rat and human
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type II 5a-reductase show a narrow acidic pH-opti- 
mum, while both type I isozymes have a broad pH- 
optimum of 6 .0-8.0  [14, 22].
In literature the pH-optimum of surmised type II 
activity in rat or human tissue homogenates differs
from pH 5.0 [14, 22], to 5.5 [12, 20, 23-26], to 6.2 
[27] or even 7.0 [28, 29]. Recent work of Thigpen et 
a l has shed new light upon the concept of pH-opti~ 
mum [30]. They postulated the efficiency optimum
Unlike the classical pH-optimum which 
only determines velocities at a single substrate con­
centration, the efficiency optimum has the advantage 
of taking into account the substrate dependency of 
enzyme reaction velocity. However, apparent affinity 
constants (K m*s) for 5a-reductase isozymes differ 
widely in literature [cf. 23].
Because of these inconsistencies we set out to re­
evaluate the assay for both isozymes in two rat andro­
gen target tissues; the epididymis, containing 
predominantly type II 5a-reductase [1, 14], and the 
prostate, containing both subtypes [14]. We detected 
a pH-dependent non-linear time-course in the 5ot- 
reduction of T in both rat tissue homogenates which 
could be resolved by bringing the enzyme to the 
appropriate pH before the start of the reaction. 
Furthermore, we demonstrated that the reported con­
troversy about the pH-optimum of type II 5a-reduc- 
tase could, at least in part, be explained by the 
substrate dependency of 5a-reduction. Also, we inves­
tigated the pH-dependency of enzyme kinetics of both 
5a~reductase isozymes. Our results indicate an 
extreme pH-dependency of the type II isozyme with 
regard to enzyme characteristics Fmax, K m and Fmax/ 
K m. This pH-dependency could explain—in conjunc­
tion with the intricacy of establishing a pH-opti- 
mum—many of the discrepancies in affinity constants 
and velocities found in literature.
MATERIALS AND METHODS
Materials
[ 1,2,6,7-3H] Testosterone (3.74 TBq/mmol) and 
[la,2a(n)-3H] 17/?-hydroxy-5a-androstan-3-one (dihy­
dro testosterone) (2.00 TBq/mmol) were purchased 
from Amersham (Amersham, U.K .). [9 , l l -3H]5oc- 
androstane-3tf,17/?-diol (1.48 TBq/mmol) was 
obtained from D u Pont-New England Nuclear 
(Boston, MA). All radiolabelled steroids were purified 
by high performance liquid chromatography (HPLC, 
see below) before use. Testosterone was purchased 
from Steraloids (Wilton, N H ). (L+)-Ascorbic acid, 
ATP (adenosine 5'-triphosphate disodium salt) and 
EDTA (ethylenediaminetetra-acetate disodium salt 
dihydrate) were obtained from Merck (Darmstadt, 
Germany). Glutathione and a-monothioglycerol (3- 
mercapto- 1,2-propanediol) were obtained from Sigma 
Chemical (St Louis, MO). TLCK (tosyl-lysine chloro-
methyl ketone) and TPCK (tosyl-phenylalanine chlor- 
omethyl ketone) were from Calbiochem (La Jolla, 
CA) and Pefabloc was obtained from Boehringer 
(Mannheim, Germany). Diethylether (p.a.), n-hexane 
(Lichrosolv) and 2-propanol (Lichrosolv) were pur­
chased from Merck, All other chemicals used were of 
analytical grade.
Protein levels were determined by a method modi­
fied from Lowry [31] against a standard of bovine 
serum albumin (OHRD 20/21, Hoechst-Behring, 
Marburg, Germany). The assay was modified for 
microtiter-plates and had a sensitivity of 25 pig per 
well. Endogenous steroid levels were determined by 
radioimmunoassay, as described previously [32]. 
Steroid concentrations were: testosterone 0.2 nM, 
androstenedione 0.06 nM  and corticosterone 5.79 
nM in the prostate homogenate, and testosterone 0.2 
nM and androstenedione 0.05 nM  in the epididymis 
homogenate. As these concentrations are low com­
pared to the concentrations employed—and as the 
homogenates are diluted over 20-fold in the final 
assay— endogenous steroids could not interfere with 
the measurement of 5a-reductase enzyme activity.
Buffers
Homogenization buffer consisted o f 20 mM phos­
phate (Merck), 1 mM monothioglycerol and 0.25 M  
sucrose (Merck), pH 7.0. The incubation buffer con­
sisted of 200 mM Tris (2-amino-2-hy dr oxymethylpr o- 
pane-lj3-diol, Merck), citric acid monohydrate 
(Merck) and 2 mM NAD PH tetras odium salt 
(Merck) in a final volume of 1 ml, pH 4.5-8.0. Final 
assay pH was checked in control tubes without tracer, 
before and after incubation.
Tissue preparation
Wistar rats 7-13 weeks old (200-250 g) were 
killed by decapitation and whole prostates and epidi­
dymides were removed, freed of adhering fat and 
placed in liquid nitrogen for transport. Tissues were 
kept at ~80°C  or processed immediately. All subse­
quent procedures were performed on ice. Tissues 
were thawed and minced with razor blades into small 
pieces. Minced tissue was homogenized in ice-cold 
homogenization buffer with a 7 ml Dounce tissue 
grinder (Kontes Glass Co., Vineland, NJ) with a loose 
and a tight fitting pestle. The homogenate was filtered 
twice through nylon netting o f 50 and 140 mesh 
respectively to remove cell debris. By this procedure, 
without centrifugation, a full homogenate with nuclei 
and cytosol is obtained. For rat prostate the final pre­
paration contained 29.1 mg protein/ml, while rat epi­
didymis homogenate contained 1.1 mg protein/ml.
Sa-Reductase assay
Radiolabelled testosterone in ethanol was brought 
to final concentration by isotopic dilution with non­
labelled steroid in Pyrex culture tubes (borosilicate
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glass, 12 x 75 mm, Coming Inc., Corning, NY). 
Ethanol was evaporated under a miid nitrogen stream 
at room temperature. Incubation buffer was added 
and the tubes were put in a shaking water bath at 
37°C for at least 10 min before the start of the incu­
bation to ensure dissolving of substrate (97%). A tube 
with cofactor (NADPH) in incubation buffer and a 
tube with the homogenate were placed in the water 
bath for 10 min to obtain the appropriate tempera­
ture. In a number of experiments, performed to opti­
mize the assay, several anti-oxidants or protease 
inhibitors were added before pre-heating the homoge­
nate, i.e. 10 min before starting the incubation. 
Immediately after adding the cofactor (200 ¿¿1) to the 
substrate, the incubation was started by adding the 
pre-heated homogenate (10-50 ¡A). After 10-30 min 
the incubation was terminated by adding 100 ¡i\ of 3 
M NaOH. To extract metabolites, 4 ml of ice-cold 
ether was added, the tubes were capped and shaken. 
The water phase was frozen in an alcohol bath with 
dry-ice, the organic phase was decanted and evapo­
rated under nitrogen. Metabolites were dissolved in 
100 /¿I hexane for HPLC.
H PLC
Metabolized steroids were separated on a Hibar 
LiChrosorb Diol-column (length 250 mm, 5 fxm, 
Merck), equipped with a guard column (Resolve 
Silica, Waters Corp., Milford, MA). The HPLC-sys- 
tem included a Waters 610 Fluid Unit, a Waters 
600E System Controller and a Waters U6K injector. 
The isocratic flow of the mobile phase (hexane-propa- 
nol 96:4, v/v) was 1.5 ml/min at a pressure of 680 psi. 
Radioactivity was monitored with a FloOne Beta 
Radiomatic A500 radio-chromatography detector 
(Packard-Canberra Benelux, Tilburg, The 
Netherlands) with a 500 ¡A cell and a liquid scintilla­
tion flow of 1.5 ml/min (Aqua-Luma, Lumac-LSC, 
Olen, Belgium). The counting efficiency for tritium 
was 47%. The percentage formation of D H T  and 5a- 
androstane-3a//?,17/?-diol were used to estimate 5a- 
reductase activity. Overall experimental recoveries for 
testosterone, dihydro testosterone and 5a-androstane- 
3a,17/?-diol were 90-93%.
Enzyme, characteristics
5a-reductase enzyme characteristics were obtained 
by the Lineweaver-Burke method with a double reci­
procal plot of velocity against substrate concentration 
at pH 4.5-8.0. Affinity constants (K mys) and maxi­
mum velocities (Pmax) were determined and the effi­
ciency ratio Vmax/K m was calculated.
RESULTS
Enzym e stability
Initially, cofactor was added to the incubation mix­
ture containing substrate, and the reaction was started 
by adding the pre-heated homogenate. Measured 
velocities, however, differed with time used to pre­
heat the homogenate. The enzyme appeared to be 
unstable at 37°C. Within 10 min only 8% of the total 
enzyme activity could yet be recovered. This applied 
to 5a-reductase isozymes type I and II in both rat 
tissues. 1 mM monothioglycerol was added to the 
homogenization buffer beforehand. Neither anti-oxi­
dants (ascorbic acid (50 mg/1) or glutathione (10 mg/ 
1), or both), nor EDTA (1 mM), ATP (2 mM), nor 
pro teas e-inhibitors [Pefabloc (100 mM ), TPCK (200 
mM) or TLCK (100 mM), alone or simultaneously], 
prevented the deterioration of enzymatic activity at 
37°C. After the enzyme had deteriorated, adding 
NADPH before starting the incubation did not restore 
enzyme activity. However, adding N A D PH  before the
10 min pre-heating of the homogenate greatly pre­
served enzymatic activity. Keeping the homogenate on 
ice with NADPH  until adding it to the incubation 
mixture gave best results, preserving 80% of enzyme 
activity. Although the homogenate then would not 
attain the appropriate temperature at the start of the 
incubation, we used this protocol in the subsequent 
study.
Non-linear time-course
The time-course in metabolism can be considered 
linear, allowing for a single time point measurement 
to estimate initial velocities, until substrate depletion 
leads to a substantial decrease in velocity. Percentual 
conversion of T  to D H T  was not allowed to exceed 
15%, by varying incubation times with different sub­
strate concentrations, to prevent this substrate deple­
tion. Analysis of the time-course of testosterone 
metabolism, however, showed an “initial burst” : in 
the first 30 s the measured velocity was higher than 
during the subsequent 10 min. This phenomenon was 
observed only at acidic pH in both rat prostate and 
epididymis homogenates [Fig. 1(A and B)]. For the 
type I isozyme, in rat prostate homogenate at pH 7.0, 
the time-course of testosterone metabolism was linear 
[Fig. 1(C)]. The initial burst precluded the correct 
estimation of initial velocities of 5a-reductase type II 
at acidic pH in a one-time point measurement.
In our initial protocol pH was presumably obtained 
almost immediately, as the homogenization buffer was 
a 20 mM phosphate buffer, the incubation buffer 
used was a 200 mM Tris-citrate buffer and only 10- 
50 /.fl of the homogenate were added to a final volume 
of 1 ml incubation buffer of the appropriate pH. 
However, bringing the enzyme to pH before starting 
the incubation by adding 0.2 ml o f incubation buffer
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Fig. 2, pH dependency o f T conversion in: (A) rat prostate 
homogenate; and (B) rat epididym is homogenate. 5a-reduc- 
tion was assessed with 1 /iM T ( # )  or with 10 nM T (A) at 
pH 4 .0-8.0 as described in M aterials and Methods. The opti­
m um  pH for the type II isozym e at acidic pH  is dependent on
the substrate concentration used.
5a-reductase, and at pH 6 .0-8 .0 , the optimum 
described earlier of the type I isozyme. Rat epididymis 
showed high type II activity at acid pH, but only mini­
mal activity at pH 6.0-8 .0  [Fig. 2(B)], The type II 
5a-reductase isozyme has been reported to have a nar­
row pH-optimum of either pH 5.0 or 5,5. In our 
hands both pHs were optimal^ albeit under different 
conditions [Fig. 2 (A and B)]. A careful analysis of 
substrate dependency at both pH's showed that at tes­
tosterone concentrations above 80 nM  an optimum of 
pH 5.0 would be found, whereas smaller amounts of 
testosterone are metabolized more efficiently at pH 
5.5 [Fig. 3 (A and B)]. The type II isozyme in the rat 
prostate shows the same substrate-dependency at 
acidic pH as in the epididymis. In the epididymis only 
a low maximum velocity, with a high affinity, is 
attained at pH 7.0 [Fig. 3(B)]. In rat prostate homo-
of the appropriate pH to the homogenate, the “ initial Senate tyPe 1 isozyme (at pH 7.0) is more efficient
•  A I  J  A J  a. M i  _ -  ~
Fig. 1. Tim e-course in the conversion of T to DHT. (A) Rat 
prostate hom ogenate. (B) Rat epididym is homogenate. 5a- 
reductase was assessed at pH 5.5 using 30 nM  T as substrate. 
When the homogenate is kept in hom ogenization buffer pH  
7.0 an initial burst is found ( # ) .  W hen the enzym e is brought 
to pH 5.5 by the addition o f incubation buffer, the tim e- 
course is linear (A)* (C) In rat prostate homogenate the 
tim e-course at pH 7.0 and using 300 nM T (type I 5a-reduc- 
tase) is linear ( # ) .  The protocol and control of buffer pH are
as described in Materials and M ethods.
burst” could be prevented [Fig. 1(A and B)].
pH-dependency o f rat ScL-reductase isozymes
in metabolizing high concentrations of T  [Fig. 3(A)].
The type I isozyme in rat prostate homogenate has 
a broad classical optimal pH o f 6 .0-8.0  [Fig. 2(A)], 
Enzyme characteristics Km axa - ^ m  * * n d  I^m ax/K m for this
pH-profiles showed that rat prostate contains both isozyme did not differ substantially in this pH-range 
5a-reductase isozymes [Fig. 2(A)]: enzyme activity [Fig. 4 (A, B and C)]. The enzyme characteristics for 
can be detected at pH 5 .0 -5 .5 , indicative of type II the type II isozyme, however, differed widely. At
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Fig. 3. Substrate dependency of pH -optim um . (A) Rat prostate homogenate. (B) Rat epididymis hom ogenate. 
5a-reductase enzyme activity was assessed at pH 5.0 (O )j at pH 5.5 ( 0 )  and at pH 7.0 (A)- At low substrate con­
centrations in both tissues the highest initial velocity is found at pH 5.5. Higher T concentrations are m ore effi­
ciently metabolized at pH 5.0. At T concentrations higher than pH 7.0 would becom e optim al in rat
prostate, but not in rat epididymis homogenates.
acidic pH; Vmax and K m showed a strong pH-depen- 
dency in both tissues (Fig. 4). At pH 4.5-6.0 VmaK 
and K m varied by a factor of 20. The efficiency ratio
was also extremely pH-dependent in the 
acidic range and had an optimum at pH 5.5 in rat 
prostate and epididymis [Fig. 4(C and F )].
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Fig. 4. Enzyme characteristics Fmax (A, D ), (B, E) and VmaxfKiri (C, F) at pH 4.75-7.5 (rat prostate A, B, C) 
and pH 4.5-8.0 (rat epididymis D , E , F). Pma* and Km were determined by a double reciprocal plot o f estim ated  
initial velocity against substrate concentration according to Lineweaver-Burke. The vs pH shows the pH-
optimum at high (saturating) substrate concentrations. i7max^m plotted vs pH shows its pH -optim um  at pH 5.5 
in both tissue homogenates. In both tissues enzyme characteristics vary m any-fold, especially at acidic pH.
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DISCUSSION
Several papers have shown the existence of at least 
two isozymes of 5a-reductase in both rat [14, 16, 21] 
and human [16* 17, 22] tissues. Most recent research 
has focused on the measurement of 5a-reductase 
mRNA and 5a-reductase expressed in transfected cell 
systems [15-17, 21, 30, 33, 34], However, correlation 
between mRNA level and assayable 5a-reductase 
activity (protein) is sometimes poor, especially in 
human tissues [1, 22, 35]. Therefore research at the 
protein level is still warranted. As kinetic data con­
cerning 5a-reductase differ widely in literature, 
reported affinity constants of testosterone for 5 a- 
reductase range from 10 nM to 15 /¿M [23* 30], we 
reevaluated the assay of this enzyme in two androgen- 
dependent rat tissues, the prostate and the epididymis. 
We used a full homogenate to keep conditions as 
close to the in vivo  environment as is possible in this 
kind of in vitro measurements. In rat prostate both 
isozymes type I (with a physiological pH-optimum) 
and type II (acidic pH-optimum) are found [14]. In 
rat epididymis the pH-optimum suggests mainly type 
II 5a-reductase activity [14], as does the apparent affi­
nity constant at pH 7,0 (see below).
A major problem we initially encountered was the 
instability of both isozymes at 37°C, Anti-oxidants 
and protease inhibitors could not prevent this dete­
rioration of enzyme activity and neither ATP nor 
EDTA did influence 5a-reductase activity. It has been 
established that N A D PH  binds to 5a-reductase first, 
allowing T  to bind subsequently [36, 37]. Liang et a l 
reported that inactivation of human and dog 5 a- 
reductase preparations could be prevented by addition 
of the cofactor NADPH  while homogenizing the tis­
sues [38]. Mutant human 5a-reductase enzymes in 
both fibroblasts and transfected cells with a shorter 
half-life than normal enzyme preparations have been 
reported with a lower affinity for NADPH  [1, 4, 18, 
20]. A role for the cofactor to stabilize the enzyme in 
the cell and to regulate enzyme turnover has been 
suggested [4]. Therefore, we investigated the influ­
ence of adding NADPH  on the encountered enzyme 
deterioration. In our hands* N A D PH  pre-binding had 
a pronounced stabilizing effect on both rat isozymes, 
but could not restore enzyme activity after pre-heating 
at 37°C. Several studies have shown the importance 
of specific membrane components and the effect of 
phospholipases, which would influence membrane 
fluidity* on 5a-reductase enzyme activity [39, 40]. 
During cell homogenization perturbations in the 
membrane environment of the tightly membrane- 
bound enzyme might cause a conformational change 
in the protein. Binding of the cofactor might make the 
enzyme less susceptible to these membrane perturba­
tions during homogenization, leaving the enzyme 
receptive for testosterone binding and metabolism.
Apart from the deterioration of 5a-reductase activity 
which could be prevented by the addition of 
NADPH, we encountered a non-linear time-course in 
the metabolism of testosterone at acidic pH in both 
rat epididymis and prostate (Fig, 1), Earlier the group 
of Martin et a l reported that the 5a-reductase in the 
particulate fraction of BPH homogenates also did not 
follow first-order Michaelis-Menten kinetics due to a 
similar non-linear time-course at pH 5.5 [23, 41, 42], 
This would have a profound effect on the measure­
ment of enzyme characteristics iCm and Fmax, when a 
single time point measurement is used. When we 
brought the tissue homogenate to the desired pH  
before starting the incubation, a linear time-course 
was obtained. In rat prostate high substrate concentra­
tions are efficiently metabolized at neutral pH by the 
type I isozyme. A sudden pH-shift from neutral to 
acidic pH might explain the initial burst encountered 
in this tissue, when one assumes that at the start of 
the incubation a part of the substrate is metabolized 
by the type I isozyme, cD N A  for type I 5a-reductase 
has been derived from the human prostate, although 
an acidic pH-optimum of enzyme activity in prostate 
extracts is found [22], typical for the type II isozyme. 
Recent evidence, however, does suggest the expres­
sion of type I 5a-reductase activity (P.M. Martin &
F.K. Habib, pers. comm.). Also in rat epididymis no 
[1, 14] or only minimal [43] type I 5a-reductase activ­
ity is found (see below). Because of the lack of mea­
surable type I activity in rat epididymis, no higher 
velocity at any substrate concentration is found at 
neutral pH in our assay. We believe interference 
between the two isozymes does not explain the 
encountered initial burst. Rather this burst is an 
intrinsic aspect of the type II isozyme per se. The sud­
den pH-change in the micro-environment of the 
membrane-bound enzyme, when starting the reaction, 
might induce a short change in activity by influencing 
membrane fluidity and/or inducing a conformational 
change of the isozyme.
In the rat epididymis type I 5a-reductase has been 
described by immunocytochemistry [43]. Our results, 
however, are at variance with this finding. At pH 7,0 
in the rat epididymis only minimal 5a-reductase activ­
ity is found [Fig. 3(B)]. Furthermore, the affinity con­
stants we found at pH 6.0-8.0  in this homogenate are 
very low (approx. 10 nM) [Fig. 4(E)], while the type I 
isozyme has a characteristic K m for T  as high as 1 (xbA 
[Fig. 4(B)]. For the human type II isozyme, expressed 
in Chinese hamster ovary cell lines, Thigpen et a l 
established a high affinity for T  of about 10 nM at 
neutral pH [30]. Although one has to be aware of the 
species difference and the difference in experimental 
conditions (in prostate or epididymis homogenates, 
and expressed human type II enzyme in CHO cells), 
we believe that the enzyme activity at neutral pH we 
found in rat epididymis can be attributed to the type 
II isozyme. One might argue that the immunocyto-
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chemical detectable 5a-reductase type I enzyme is 
inhibited or is non-active, as also discrepancies between 
mRNA and enzyme activity have been reported in 
human BPH-tissue [22]. However, immunocytochem­
istry is much more sensitive than our biochemical assay 
and is capable of detecting extremely small amounts of 
enzyme. Furthermore, type I 5a-reductase is reportedly 
highly concentrated in the initial segment of the epi­
didymis [43]. We might therefore not have been able 
to detect this activity in a homogenate of the whole epi­
didymis. Whether this type I activity in the rat epididy­
mis has any physiological significance, considering its 
low affinity for T, needs to be addressed in studies 
using discrete segments of this tissue.
The pH-optimum of 5a-reductase activity in rat or 
human tissue has been the subject of mild controversy. 
pH-optima in tissues considered to contain mainly type
II 5a-reductase differ in literature; an optimum of 5.0 
has been described for the type II enzyme in rat epidi­
dymis and prostate and in human prostate [14, 22], 
and an optimum of 5.5 for the human epididymis and 
BPH tissue, fibroblasts and other human and rat tissues 
[12, 20, 23-26]. In addition, an optimum of 6.2 was 
found in the rat epididymis by Mon salve and Blaquier 
[27], while the group of Houston et al. reported a pH- 
optimum of 7.0 in the human prostate [28, 29]. The 
normal procedure to obtain a pH-optimum is by incu­
bating an enzyme preparation with a single substrate 
concentration. Velocity, however, depends strongly on 
substrate concentration.
From the Michaelis-Menten equation: v = 
( I'max [S])/(Km + [S]) where [5] is the T  concentration 
follows: when S  »  i<Cm, a pH-profile would indicate
J^ max S^ pH.
And when 5  «  K m: v = The velo­
cities found are then proportional to Vmax/K m .
In this paper we described the initial velocities at 
different testosterone concentrations and pHs. At tes­
tosterone concentrations below 80 nM a higher initial 
velocity is found at pH 5.5, whereas at higher testos­
terone concentrations the optimum in rat epididymis 
was 5.0. The pH-optimum shift from pH 5.0 to 5.5 
reported for some mutant human 5oi-reductase 
enzymes might be explained by the reported change 
in substrate or cofactor affinity [4, 20]. As both testos­
terone and NADPH were kept at a constant concen­
tration in these studies, a change in affinity by a 
mutation in the enzyme can cause the chosen concen­
tration to induce a different pH-optimum, as a differ­
ent affinity constant implies a different substrate 
dependency.
Unlike the classical pH-optimum, the efficiency 
ratio Fmax/7Cm takes into account the substrate depen­
dency of velocity. This ratio also reflects the potential 
in vivo  velocity of D H T formation from T, as endo­
genous T concentrations are much lower than the 
K m. In our hands, the optimum of the efficiency ratio 
for the type II isozyme was at pH 5.5 in rat prostate
and epididymis. This ratio has been reported to be 
optimal at pH 6.0 for a microsomal preparation of 
human prostatic tissue [44] or at pH 7.0 for the 
expressed human type II isozyme in a hamster ovary 
cell line [30]. Preliminary results from our laboratory 
also indicate that the efficiency optimum in human 
BPH tissue homogenate is at pH 6.5 (unpublished 
observations). In rat prostate both 5oi-reductase iso­
zymes are present, so the Vmax/K m ratio for the rat 
type II isozyme at neutral pH cannot be determined 
in this tissue, as at this pH the type I isozyme will 
interfere. Because of the high K m of the type I iso­
zyme, low efficiency ratios are found at neutral pH in 
rat prostate. The low efficiency ratio at this pH in rat 
epididymis, however, cannot be explained by the pre­
sence of type I 5a-reductase. In contrast to the rat 
prostate, affinity constants are 100-fold lower at neu­
tral pH in the epididymis. The decreased Fmax/i<rm 
ratio at pH 6.5-8.0 in this tissue is caused by the 10- 
fold lower J/max at this pH as compared to pH 5.5, 
with similar affinity constants.
Since we found the enzyme characteristics Vmax and 
K m to be highly dependent on minor pH-changes in 
the acidic pH region, the choice of pH has consider­
able effects on reported kinetic data. Some effects of 
modifying substances might be explained by even 
minor shifts in the pH during the assay (as reported 
in 45 for EDTA).
The present study discloses that in rat prostate and 
epididymis homogenates the metabolism of T at 
acidic pH by the type II 5a-reductase isozyme shows a 
non-linearity in the time-course when not brought to 
the desired pH before the start of the incubation. 
Therefore estimation of initial velocities at acidic pH 
in these tissues is incorrect in a single time point mea­
surement. Bringing the enzyme to the appropriate pH 
before the start of the incubation leads to a linear 
time-course. When a pH-optimum is attained one has 
to consider the substrate dependency of enzyme reac­
tion velocity. At high substrate concentrations a pH- 
optimum of pH 5.0 is found for the rat type II iso­
zyme, while at low substrate concentrations an opti­
mum of pH 5.5 is found, equalling the Fmax/i<Cm 
efficiency ratio pH-optimum in rat prostate and epidi­
dymis homogenates. The extreme pH-dependency of 
the rat type II 5a-reductase isozyme strongly influ­
ences enzyme characteristics. The choice of pH for 
the assay o f 5a~reductase type II could explain discre­
pancies in reported affinity constants in literature.
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